Patent · US Active

Crystalline form F of Imatinib mesylate

US7893076B2 · kind B2 · utility

2Cited by

0References

8Claims

0Family size

Assignees

Novartis AG · CH
Novartis Pharma AG · CH

Inventor

Michael Mutz · Glückstadt, DE

Key dates

Filing date	Nov 23, 2006
Grant date	Feb 22, 2011
Priority date	—
Expiry date	Dec 27, 2026

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D401/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the F-crystal form, G-crystal form, H-crystal form, I-crystal form and K-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, certain processes for their preparation, pharmaceutical compositions containing these crystal forms, their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, especially humans.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.